Abstract
Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.
Keywords: Recombinant human relaxin, acute heart failure, cardiovascular, endothelium-derived hyperpolarization, homeostasis, nitric oxide, prostacyclin, vasoconstrictors.
Graphical Abstract
Current Protein & Peptide Science
Title:Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction
Volume: 19 Issue: 11
Author(s): Ghulam Murtaza*, Adeel Siddiqui and Izhar Hussain
Affiliation:
- Department of Pharmacy, COMSATS University Islamabad, Lahore Campus,Pakistan
Keywords: Recombinant human relaxin, acute heart failure, cardiovascular, endothelium-derived hyperpolarization, homeostasis, nitric oxide, prostacyclin, vasoconstrictors.
Abstract: Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.
Export Options
About this article
Cite this article as:
Murtaza Ghulam *, Siddiqui Adeel and Hussain Izhar , Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction, Current Protein & Peptide Science 2018; 19 (11) . https://dx.doi.org/10.2174/1389203719666180709103020
DOI https://dx.doi.org/10.2174/1389203719666180709103020 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Cardioprotective Effects of Serca2a Overexpression Against Ischemiareperfusion- induced Injuries in Rats
Current Gene Therapy Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews The Muscular Dystrophies Associated with Central Nervous System Lesions: A Brief Review from a Standpoint of the Localization and Function of Causative Genes
Current Pediatric Reviews Vasoprotective Actions of the Atrial Natriuretic Peptide
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Human Imprinting Anomalies in Fetal and Childhood Growth Disorders: Clinical Implications and Molecular Mechanisms
Current Pharmaceutical Design Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Patent Selections
Recent Patents on Regenerative Medicine Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry The Effects of Vitamin C on Adriamycin-Induced Hypercholesterolemia in Rat
Current Nutrition & Food Science The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Isoindole Derivatives: Propitious Anticancer Structural Motifs
Current Topics in Medicinal Chemistry Glucose Sensing in Chondrocytes via GLUT1 and GLUT3: Implications for Articular Cartilage and Intervertebral Disc Metabolism
Current Rheumatology Reviews Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Nongenomic Actions of Thyroid Hormones: From Basic Research to Clinical Applications. An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)